| (Values in U.S. Thousands) | Dec, 2018 | Dec, 2017 | Dec, 2016 | Dec, 2015 | Dec, 2014 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -4,550 | -5,100 | -7,000 | -3,950 | -3,980 |
| Net Income Growth | +10.78% | +27.14% | -77.22% | +0.75% | -117.49% |
Hedgepath Pharmaceuticals Inc (HPPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
HedgePath Pharmaceuticals, Inc. is a biopharmaceutical company which discovers and develops therapeutics for cancer primarily in the United States. It focuses on the development of Hedgehog pathway inhibitor therapeutics for various cancers which includes skin, prostate and lung cancers. HedgePath Pharmaceuticals, Inc., formerly known as Commonwealth Biotechnologies, Inc., is based in Tampa, Florida.